Copyright
©The Author(s) 2021.
World J Hepatol. Feb 27, 2021; 13(2): 261-269
Published online Feb 27, 2021. doi: 10.4254/wjh.v13.i2.261
Published online Feb 27, 2021. doi: 10.4254/wjh.v13.i2.261
Ref. | Year | Type of study | Pts included, n | CRLM1, n (%) | Tumor location (n) | Bilobar n (%) | Prior resection, n (%) | Resectability, n (%) |
Gray et al[18] | 2001 | HAI vs HAI + TARE in unresectable CRLM; RCT | 74 | 36 (48.6) | Colon (29), rectum (7) | 36/36 (100) | 0 | 1/36 (2.8) |
Lim et al[6] | 2005 | TARE after failure of FU in unresectable CRLM; prospective | 30 | 30 (100) | NA | NA | 0 | 1/30 (3.3) |
Sharma et al[7] | 2007 | TARE + FOLFOX4 in unresectable CRLM; prospective (phase I) | 20 | 20 (100) | Right colon (4), sigmoid (5), rectum (4), other colon sites (7) | NA | 0 | 2/20 (10) |
Cosimelli et al[19] | 2010 | TARE in unresectable CRLM; prospective (phase II) | 50 | 50 (100) | Colon (41), rectum (9) | 35/50 (70) | 12/50 (24.0) | 2/50 (4.0) |
Hendlisz et al[8] | 2010 | FU vs TARE + FU in unresectable CRLM; RCT | 44 | 21 (47.7) | NA | NA | NA | 1/21 (4.8) |
Brown et al[9] | 2011 | TARE vs CHT vs no therapy before hepatectomy; case-control | 840 | 16 (1.9) | NA | NA | NA | 16/16 (100) |
Whitney et al[10] | 2011 | TARE in unresectable liver disease; retrospective | 44 | 15 (34) | Rectum (15) | 0 | 0 | 1/15 (6.7) |
Vouche et al[11] | 2013 | TARE in unresectable liver disease; retrospective | 83 | 8 (9.6) | NA | 0 | 0 | 1 (12.5) |
Wang et al[20] | 2013 | TARE before liver resection for CRLM; retrospective | 24 | 24 (100) | Sigmoid (1), rectum (1), other colon sites (1), unknown (21) | 1/3 (33.3) | 0 | 3/24 (12.5) |
Henry et al[12] | 2015 | TARE before liver resection for metastatic cancer; retrospective | 9 | 4 (44.4) | NA | NA | 0 | 4/4 (100) |
Justinger et al[22] | 2015 | TARE in marginally resectable CRLM; retrospective | 13 | 13 (100) | Right colon (2), sigmoid (4), rectum (7) | 9/13 (69.2) | 7/13 (53.8)2 | 11/13 (84.6) |
Moir et al[13] | 2015 | TARE in unresectable liver disease; retrospective | 44 | 22 (50) | NA | NA | NA | 4/22 (18.2) |
Maleux et al[14] | 2016 | TARE in unresectable CRLM; NA | 88 | 71 (80.6) | NA | 58/71 (81.6) | 10/71 (14.0) | 1/71 (1.4) |
Lewandowski et al[23] | 2016 | TARE in unresectable right-sided liver disease; retrospective | 13 | 1 (7.6) | NA | 0 | NA | 1/1 (100) |
Wright et al[15] | 2017 | TARE in unresectable liver disease; retrospective | 465 | 6 (1.2) | NA | NA | NA | 6/6 (100) |
van Hazel et al[16] | 2016 | FOLFOX6 vs FOLFOX6 + TARE ± Bevacizumab; RCT | 530 | 267 (50.3) | Left colon (141), right colon (72), rectum (45), other colon sites (7), unknown (2) | NA | NA | 38/267 (14.2) |
Pardo et al[21] | 2017 | TARE before liver resection or transplantation; retrospective | 100 | 30 (30) | NA | 44/100 | 7/30 (23.3)2 | 30/30 (100) |
Wasan et al[17] | 2017 | FOLFOX vs FOLFOX + TARE; RCT | 1103 | 554 (50.2) | Colon (421), rectum (116), unknown (17) | NA | NA | 56/554 (10.1) |
Ref. | FLR increase % | Time TARE-surgery, median (range), mo | Type of hepatic resection (n) | Post-operative mortality % | Survival, median (range), mo | Disease free, median (range), mo | Recurrence after surgery, n (%) |
Gray et al[18] | NA | NA | NA | 0 | 96 | NA | NA |
Lim et al[6] | NA | NA | NA | NA | NA | 22 | 1/1 (100) |
Sharma et al[7] | NA | NA | LLS + S6 (1), RH + S3 (1) | NA | NA | NA | NA |
Hendlisz et al[8] | NA | NA | RH (1) | 0 | NA | 1.5 | 1/1 (100) |
Brown et al[9] | NA | 6.5 (4-13) | NA | NA | NA | NA | NA |
Whitney et al[10] | NA | NA | RT (1) | 0 | NA | 24 | 1/1 (100) |
Vouche et al[11] | NA | NA | RT (1) | 0 | NA | NA | NA |
Wang et al[20] | NA | NA (4-9) | RH (2), LH + S6 (1) | 0 | NA | NA | NA |
Henry et al[12] | NA | 5 (2-8) | LLS (1), multiple wedge, HAI pump (1), RT + RFA (1), RT (1) | 50 | 13 (0-27) | 6.2 (1.8-10.5) | 3/4 (75) |
Justinger et al[22] | 32.9 (ALPPS), 27.1 (no ALPPS) | 2 (1-5) | RT (4), RH (5), mesohepatectomy (1), LT (1) | 7.6 | 25 (12-38)1 | NA | NA |
Moir et al[13] | NA | 4 (2-11) | NA | 0 | 15 (11-19)1 | NA | NA |
Maleux et al[14] | NA | NA | S + RFA (1) | 0 | NA | NA | NA |
Lewandowski et al[23] | 15 | 1.6 (1-7) | RT (1) | 0 | 4.8 | NA | NA |
Wright et al[15] | NA | 9 (3-20) | RT (2), S (1), RH (3) | 16.6 | 25 (NA) | NA | NA |
van Hazel et al[16] | NA | NA | NA | 0 | NA | NA | NA |
Pardo et al[21] | NA | NA | NA | 10 | NA | NA | NA |
Wasan et al[17] | NA | NA | NA | 3.6 | NA | NA | NA |
- Citation: Serenari M, Neri J, Marasco G, Larotonda C, Cappelli A, Ravaioli M, Mosconi C, Golfieri R, Cescon M. Two-stage hepatectomy with radioembolization for bilateral colorectal liver metastases: A case report. World J Hepatol 2021; 13(2): 261-269
- URL: https://www.wjgnet.com/1948-5182/full/v13/i2/261.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i2.261